VID27 Antibody

What is VID27 and why is it significant in cellular research?

VID27 (Vacuolar Import and Degradation 27) is a cytoplasmic protein that is crucial for the delivery of fructose-1,6-bisphosphatase into VID vesicles in yeast cells . This protein is significant in cellular research because it represents an important component in the molecular machinery governing protein trafficking and degradation pathways. The study of VID27 has revealed connections between ubiquitination processes and vacuolar protein sorting, which are fundamental cellular mechanisms conserved across eukaryotes. Understanding VID27 function contributes to our knowledge of how cells maintain protein homeostasis and respond to changing nutrient conditions, particularly during the transition from gluconeogenic to glycolytic metabolism.

What methodologies are commonly used to generate antibodies against VID27?

Generating antibodies against yeast proteins like VID27 typically involves several methodological approaches:

• Recombinant protein expression: Express full-length VID27 or specific domains in bacterial or insect cell systems with appropriate affinity tags for purification.

• Peptide-based immunization: Design synthetic peptides corresponding to immunogenic epitopes of VID27, typically 15-20 amino acids in length from hydrophilic, surface-exposed regions.

• Immunization protocols: Either polyclonal antibodies can be generated in rabbits or other host animals, or monoclonal antibodies can be developed using hybridoma technology following mouse immunization.

• Computational epitope prediction: Modern antibody development often employs in silico analysis to identify optimal antigenic determinants, similar to approaches used in recent computational antibody design systems .

• Epitope mapping: After antibody generation, epitope mapping techniques such as phage display or peptide arrays can be employed to precisely determine the binding region on VID27.

The choice between these approaches depends on the specific research requirements and the structural characteristics of the VID27 protein.

How should researchers validate the specificity of VID27 antibodies?

Rigorous validation of VID27 antibodies is essential for research integrity and involves multiple complementary techniques:

• Western blotting: Demonstrate single-band detection at the expected molecular weight (~75 kDa) in wild-type yeast extracts, with absence of signal in VID27 deletion mutants.

• Immunoprecipitation: Confirm ability to specifically immunoprecipitate VID27 from cell lysates, validated by mass spectrometry.

• Immunofluorescence microscopy: Verify correct subcellular localization pattern matching known VID27 distribution, with appropriate controls.

• Cross-reactivity testing: Assess potential cross-reactivity against related proteins, particularly other components of the VID pathway.

• Genetic controls: Compare antibody reactivity between wild-type and VID27 mutant or knockout strains to confirm specificity .

• Epitope competition assays: Perform blocking experiments using the immunizing peptide or recombinant protein to demonstrate binding specificity.

A systematic validation approach combining multiple methods provides the highest confidence in antibody specificity and suitability for experimental applications.

How can computational antibody design approaches be applied to generate VID27-specific antibodies?

Recent advances in computational antibody design, exemplified by systems like JAM, offer promising approaches for generating VID27-specific antibodies:

• Structure-based design: Using available structural data or homology models of VID27, computational systems can design antibodies that target specific epitopes with high specificity.

• De novo antibody generation: Advanced systems can generate completely novel antibody sequences tailored to VID27 epitopes without requiring pre-existing antibody templates .

• Format flexibility: Computational approaches can design various antibody formats including single-domain (VHH) and paired (scFv/mAb) formats depending on research requirements .

• Epitope-focused design: Target precise functional domains of VID27, such as regions involved in fructose-1,6-bisphosphatase binding or regions that mediate interactions with other vacuolar sorting components.

• Iterative optimization: Implementation of machine learning approaches that allow iterative refinement of designs to improve binding affinity and specificity, as demonstrated with the JAM system where "test-time computation by allowing iterative introspection on outputs substantially improves both binding success rates and affinities" .

The process would involve:

• Inputting VID27 amino acid sequence and structure

• Defining target epitopes relevant to VID27 function

• Generating and screening antibody designs computationally

• Experimental validation through yeast display and more rigorous characterization methods

This approach can significantly accelerate antibody development timeframes, with some systems reducing the design-to-characterization process to less than 6 weeks .

What role does VID27 play in the suppression of doa4 phenotypes and how can antibodies help investigate this interaction?

VID27 has been implicated in preventing the suppression of the doa4 phenotype by did3 mutation, revealing a complex interplay between deubiquitination processes and vacuolar protein sorting . Antibodies can serve as powerful tools to investigate this interaction through several advanced methodological approaches:

• Co-immunoprecipitation studies: VID27 antibodies can be used to pull down protein complexes to identify direct or indirect interactions with Doa4 and DID proteins under various conditions.

• Proximity labeling techniques: VID27 antibodies conjugated to enzymes like BirA* or APEX2 can facilitate proximity-dependent biotinylation to map the protein neighborhood of VID27 in live cells.

• Super-resolution microscopy: Using fluorophore-conjugated VID27 antibodies in techniques like STORM or PALM to visualize co-localization with Doa4 and related proteins at nanometer resolution.

• Chromatin immunoprecipitation (ChIP): If VID27 has any nuclear roles, ChIP using VID27 antibodies can reveal potential roles in transcriptional regulation of genes related to the doa4 phenotype.

• FRET/FLIM analysis: Antibody fragments labeled with appropriate fluorophores can be used to detect direct protein-protein interactions between VID27 and Doa4 pathway components.

The evidence that "inactivation of Vid27 prevents suppression of the doa4 phenotype by did3 mutation" suggests that VID27 antibodies could be particularly valuable for dissecting the sequential events in this pathway and understanding the mechanistic basis of this genetic interaction.

What considerations should researchers make when designing experiments to study VID27 interactions with the vacuolar protein sorting machinery?

When designing experiments to study VID27's interactions with vacuolar protein sorting machinery, researchers should consider several methodological factors:

• Temporal dynamics: VID27's role in fructose-1,6-bisphosphatase delivery suggests condition-dependent activity. Experiments should include time-course analyses during metabolic shifts (e.g., glucose to non-fermentable carbon sources).

• Compartment-specific isolation: Given VID27's involvement in vesicular transport, subcellular fractionation techniques should be optimized to preserve transient vesicular intermediates.

• Genetic background considerations: Experiments should be performed in both wild-type and mutant backgrounds (doa4Δ, did3Δ, etc.) to fully understand epistatic relationships .

• Protein complex stability: Use of crosslinking agents before immunoprecipitation with VID27 antibodies may be necessary to capture transient interactions within the sorting machinery.

• Technical controls for antibody studies:

  • Include VID27 deletion strains as negative controls

  • Use epitope-tagged VID27 constructs as complementary approaches

  • Consider competitive binding assays to verify specificity

• Mutational analysis: Combine VID27 antibodies with systematic mutagenesis of key residues to map functional domains involved in protein sorting interactions.

• Integrated multi-omics approach: Combine antibody-based proteomics with transcriptomics and metabolomics to develop comprehensive models of VID27's role in vacuolar sorting networks.

A table summarizing the recommended experimental approaches for different research questions related to VID27:

How can epitope mapping inform the development of function-blocking VID27 antibodies?

Epitope mapping provides crucial information for developing function-blocking VID27 antibodies that can serve as molecular tools to dissect protein function:

• Structural determination of functional domains: Comprehensive epitope mapping can identify critical regions of VID27 involved in protein-protein interactions or enzymatic activity. Recent advances in computational antibody design have demonstrated that "epitope mapping and in silico docking analysis show that mAb binding to membrane-distal and external-facing residues are stronger agonists" , principles which could be applied to develop VID27-targeting antibodies.

• Rational design approach:

  • Identify conserved functional motifs in VID27 sequences across species

  • Target regions predicted to be involved in fructose-1,6-bisphosphatase binding

  • Design antibodies against domains mediating interactions with vacuolar sorting machinery

• Experimental mapping methodology:

  • Use hydrogen-deuterium exchange mass spectrometry (HDX-MS) to identify solvent-exposed regions

  • Employ peptide arrays or phage display libraries with overlapping VID27 fragments

  • Validate epitopes through site-directed mutagenesis of predicted binding residues

• Function-correlation studies: Systematically correlate epitope binding with functional outcomes, such as inhibition of fructose-1,6-bisphosphatase trafficking or disruption of interactions with vacuolar sorting components.

• Application of computational design: Utilize advanced computational approaches similar to JAM that can generate antibodies with "precise epitope targeting without experimental optimization" .

The development of a panel of epitope-specific antibodies targeting different functional domains of VID27 would provide researchers with a molecular toolbox to selectively inhibit specific aspects of VID27 function, enabling more precise dissection of its roles in vacuolar protein sorting and metabolic regulation.

What are the challenges in generating antibodies against yeast proteins like VID27, and how can they be overcome?

Generating high-quality antibodies against yeast proteins like VID27 presents several specific challenges that can be addressed through strategic methodological approaches:

• Evolutionary distance challenge: The significant evolutionary distance between yeast and traditional immunization hosts (mammals) can result in either hyper-immunogenicity or ineffective immune responses.

  • Solution: Employ strategic epitope selection using in silico tools to identify regions with balanced immunogenicity and implement step-wise immunization protocols with gradually increasing antigen complexity.

• Structural complexity: Yeast-specific post-translational modifications or folding patterns may not be replicated in recombinant expression systems.

  • Solution: Express VID27 in yeast-based expression systems rather than bacterial systems to preserve authentic folding and modifications. Alternatively, computational design approaches can be used to generate antibodies that recognize native epitopes without requiring immunization .

• Cross-reactivity concerns: Antibodies might recognize conserved domains in related proteins.

  • Solution: Comprehensive cross-reactivity testing against proteome arrays and advanced affinity maturation techniques to enhance specificity. The JAM system demonstrates how "increasing test-time computation by allowing iterative introspection on outputs substantially improves binding success rates and affinities" .

• Validation limitations: Limited availability of knockout strains or cellular materials for validation.

  • Solution: Create CRISPR-based knockout or epitope-tagged knock-in strains specifically for antibody validation. Implement orthogonal validation techniques including mass spectrometry-based approaches.

• Low abundance target: VID27 may be expressed at low levels under standard conditions.

  • Solution: Induce expression under conditions known to upregulate VID27 (e.g., during gluconeogenesis) or use targeted enrichment strategies before immunization or screening.

A systematic approach combining these solutions can significantly improve success rates in generating specific and functionally relevant antibodies against challenging yeast targets like VID27.

How can VID27 antibodies be used to study the relationship between ubiquitination and vacuolar protein sorting?

VID27 antibodies represent powerful tools for investigating the complex relationship between ubiquitination and vacuolar protein sorting, which has been highlighted by the finding that VID27 is connected to Doa4, a deubiquitinating enzyme involved in the late endosome/pre-vacuolar compartment :

• Ubiquitination profiling: VID27 antibodies can be used in immunoprecipitation experiments followed by ubiquitin-specific western blotting to characterize the ubiquitination state of VID27 and its binding partners under various conditions.

• Deubiquitination dynamics: Since "DUB Doa4 is involved in deubiquitination of conjugates at the late endosome/pre vacuolar compartment" , VID27 antibodies can help track how deubiquitination events influence the localization and function of VID27.

• Sequential immunoprecipitation approach:

  • First IP: Capture ubiquitinated proteins using anti-ubiquitin antibodies

  • Second IP: Use VID27 antibodies to isolate the subset of ubiquitinated proteins associated with VID27

  • Analysis: Mass spectrometry to identify specific ubiquitination sites and interaction partners

• In situ proximity ligation assays: Combine VID27 antibodies with antibodies against ubiquitin or specific ubiquitin ligases/deubiquitinases to visualize direct interactions in intact cells.

• Correlative microscopy: Use fluorescently-labeled VID27 antibodies in combination with ubiquitin sensors to track dynamic changes in ubiquitination at VID27-positive structures.

• Functional reconstitution: Develop in vitro systems using purified components and VID27 antibodies to reconstitute and manipulate the ubiquitination/deubiquitination cycles that influence VID27 function.

This multi-faceted approach using VID27 antibodies would provide mechanistic insights into how "ubiquitination is a key regulatory mechanism that affects numerous cellular processes" in the context of vacuolar protein sorting pathways.

What advanced imaging techniques can be combined with VID27 antibodies to study vesicular trafficking?

Combining VID27 antibodies with cutting-edge imaging techniques offers powerful approaches to investigate the dynamic processes of vesicular trafficking:

• Live-cell super-resolution microscopy:

  • Directly conjugate fluorophores to Fab fragments of VID27 antibodies

  • Implement STORM, PALM, or STED microscopy to achieve 20-50 nm resolution

  • Track individual VID vesicles containing fructose-1,6-bisphosphatase in real-time

  • Correlate with markers for class E compartments to visualize sorting events

• Multi-color 4D imaging:

  • Combine spectrally distinct fluorophore-conjugated antibodies against VID27 and other pathway components

  • Implement lattice light-sheet microscopy for high-speed, low-phototoxicity volumetric imaging

  • Capture the entire trafficking process from cytoplasm to vacuole with millisecond temporal resolution

• Correlative light and electron microscopy (CLEM):

  • Use gold-conjugated VID27 antibodies for immunoelectron microscopy

  • Correlate fluorescence signals with ultrastructural details of vesicular intermediates

  • Implement focused ion beam scanning electron microscopy (FIB-SEM) for 3D reconstruction

• Förster resonance energy transfer (FRET):

  • Engineer donor-acceptor pairs on VID27 antibodies and putative interaction partners

  • Measure FRET efficiency to detect molecular-scale interactions during vesicle formation and fusion

  • Implement fluorescence lifetime imaging (FLIM) for quantitative interaction mapping

• Expansion microscopy:

  • Physically expand fixed samples labeled with VID27 antibodies

  • Achieve super-resolution imaging on conventional microscopes

  • Preserve spatial relationships between VID27 and vacuolar sorting machinery

These advanced imaging approaches would provide unprecedented insights into how "Vid27 is a cytoplasmic protein essential for delivery of fructose-1,6-bisphosphatase into VID vesicles" and its broader role in vacuolar protein sorting pathways.

How can researchers integrate VID27 antibody studies with systems biology approaches?

Integrating VID27 antibody studies with systems biology approaches can provide comprehensive insights into its functional networks:

• Antibody-based interactome mapping:

  • Use VID27 antibodies for immunoprecipitation followed by mass spectrometry (IP-MS)

  • Generate protein interaction networks across different metabolic conditions

  • Implement BioID or APEX proximity labeling with VID27 antibodies to capture transient interactors

• Multi-omics integration framework:

  • Combine antibody-based proteomics with transcriptomics, metabolomics, and lipidomics

  • Develop computational models that predict how VID27 perturbations affect global cellular processes

  • Identify regulatory relationships between VID27 and other vesicular trafficking components

• Perturbation-response studies:

  • Use VID27 antibodies to immunodeplete the protein from cellular extracts

  • Perform in vitro reconstitution assays to test system-level effects

  • Monitor global phosphorylation changes following VID27 disruption using phospho-proteomics

• Genetic interaction mapping:

  • Combine VID27 antibody markers with systematic genetic screens

  • Identify suppressors and enhancers of VID27-related phenotypes

  • Generate genetic interaction networks centered on VID27 function

• Mathematical modeling:

  • Develop kinetic models of VID27-dependent processes using quantitative antibody-based measurements

  • Simulate perturbations to predict system-level outcomes

  • Validate predictions experimentally using VID27 antibodies as detection tools

This integrated approach will help contextialize findings that "inactivation of Vid27 prevents suppression of the doa4 phenotype by did3 mutation" within the broader cellular systems architecture.

How might computational antibody design techniques evolve to improve the development of VID27 antibodies?

Computational antibody design for targets like VID27 is poised for significant advancements:

• Multi-epitope targeting strategies: Future computational platforms may design antibody cocktails that simultaneously target multiple functional epitopes on VID27, providing more comprehensive inhibition or detection capabilities.

• Structure-based optimization: As structural data for VID27 becomes available, computational approaches will incorporate precise structural constraints, similar to how JAM "receives a target amino acid sequence (a hard constraint) and structure (a flexible constraint), along with a list of residues that comprise the epitope" .

• Machine learning advances: Next-generation algorithms will leverage expanded training datasets to better predict antibody-antigen interactions specific to yeast proteins.

• In silico affinity maturation: Computational platforms will implement virtual affinity maturation to optimize binding properties before experimental validation, leveraging approaches where "increasing test-time computation by allowing JAM to iteratively introspect on its outputs substantially improves both binding success rates and affinities" .

• Integration with experimental feedback loops: Hybrid systems will combine computational prediction with high-throughput experimental validation in iterative cycles, continuously refining the design algorithms.

• Developability prediction: Advanced algorithms will simultaneously optimize for binding affinity and developability parameters (stability, solubility, etc.), similar to how JAM-designed antibodies demonstrated "strong early-stage developability profiles" .

• Species-specific optimization: Computational systems will be trained on yeast-specific datasets to better account for the unique challenges of generating antibodies against yeast proteins like VID27.

These advancements could dramatically reduce the time and resources required for developing highly specific VID27 antibodies, potentially condensing the entire process to "less than 6 weeks" while improving success rates and functional properties.